N
NovoCure Limited (NVCR)
NMS – Real Time Price. Currency in USD
15.43
+0.38 (2.52%)
At close: Jun 26, 2026, 4:00 PM EDT
15.13
-0.30 (-1.94%)
After-hours: Jun 26, 2026, 5:33 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
15.43
+0.38 (2.52%)
At close: Jun 26, 2026, 4:00 PM EDT
15.13
-0.30 (-1.94%)
After-hours: Jun 26, 2026, 5:33 PM EDT
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
| Name | Position |
|---|---|
| Dr. Uri Weinberg M.D., Ph.D. | Chief Innovation Officer & Chief Medical Officer |
| Mr. Adam Daney | Head of Investor Relations |
| Mr. Barak Ben-Arye | General Counsel |
| Mr. Christoph Brackmann | Chief Financial Officer |
| Mr. Frank Leonard | CEO & Director |
| Mr. Michael Puri | Chief Human Resources Officer |
| Mr. Mukund Paravasthu | Chief Operating Officer |
| Mr. William F. Doyle | Executive Chairman |
| Date | Type | Document |
|---|---|---|
| 2026-06-18 | 8-K | nvcr-20260618.htm |
| 2026-06-05 | 8-K | nvcr-20260603.htm |
| 2026-05-21 | DEFA14A | defa-14a2026proxyprop4mate.htm |
| 2026-04-30 | 8-K | nvcr-20260430.htm |
| 2026-04-30 | 10-Q | nvcr-20260331.htm |
| 2026-04-24 | 8-K/A | nvcr-20251124.htm |
| 2026-04-20 | DEFA14A | defa-14a2026proxynotice.htm |
| 2026-04-09 | 8-K | nvcr-20260408.htm |
| 2026-03-26 | 8-K | nvcr-20260326.htm |
| 2026-02-26 | S-8 | s-82026.htm |